Search
Close this search box.
Search

Novo Nordisk and Glooko team up for digital diabetes management

Mountain View, California-based Glooko Danish pharmaceutical company Novo Nordisk are going to work together to develop a digital diabetes management platform.

The partnership combines Glooko’s digital capabilities and Novo Nordisk’s deep knowledge of diabetes. Glooko offers a mobile, cloud-based platform for people with diabetes to track and manage their condition, and the app syncs with data from most diabetes and exercise devices. Novo Nordisk makes several diabetes drugs and delivery devices, and has been integrated with IBM Watson Health since December 2015 to improve diabetes care based on data collected from its devices and treatments.

“This is really exciting for us, because there has been a need for an agnostic platform that launches better data driven decisions,” said Glooko CEO Rick Altinger. “From our standpoint, we can help patients on a global basis, and this also allows us to focus more on core technology while Novo Nordisk brings that vast set of educational content and clinical research that they have developed over the years.”

Together, the companies will build on Glooko’s existing mobile and web platforms to improve population health reporting, plus create personalized digital services to support people with diabetes in areas like medication adherence and blood glucose management.

“We are excited to partner with Glooko and to take another step towards delivering digital health offerings that help people with diabetes to improve their blood glucose control,” Christian Kanstrup, Novo Nordisk’s senior vice president of Strategy, Access and Marketing, explained. “Working in partnerships will furthermore enhance our ability to demonstrate the real-world value of our portfolio of diabetes treatments.”

Glooko’s platform is used in over 48,000 health systems across 27 countries. In September, the company merged with Swedish diabetes management company Diasend to expand their technological capabilities and establish a greater global footprint. Vikram Singh, Product Analytics and Marketing Manager at Glooko, said it shows pharma’s growing embrace of digital platforms as a means of gaining more insight and feedback into how their products and treatments are performing.

“Everyone wants to know what’s happening in the wild, and a lot of companies are now running robust studies because they haven’t had the feedback loop that any software company does,” according to Singh. “We can do that, and Novo Nordisk and others have recognized that partnering with a company like Glooko means they can work on that and provide better treatments.”

Altinger pointed to the increase of outcomes-related data by Glooko and other digital diabetes management platforms that has caught the interest of device and treatment companies.  “There is increasing momentum around diabetes,” Altinger said. “It’s a costly disease; one of the most expensive chronic conditions if not only for private health plans but for government insurance plans and pharma to pay for outcomes data. Now, they are embracing that partnerships have the technology to facilitate that.”

Whixx

ICT&health World Conference 2024

Experience the future of healthcare at the ICT&health World Conference from May 14th to 16th, 2024!
Secure your ticket now and immerse yourself in groundbreaking technologies and innovative solutions.
Engage with fellow experts and explore the power of global collaborations.

Share this article!

Read also
Balancing regulatory compliance with seamless adoption, healthcare navigates the integration of AI solutions.
A guide to implementing AI in healthcare amid the EU AI Act
AmyWebb-Stephen-Olker
Futurist Amy Webb claims that wearables will evolve into "connectables"
Digital health solutions empower patients to better manage their health and integrate care into their daily lives.
How to improve Digital Patient Engagement to streamline workflows
For people with diabetes, inaccurate blood glucose measurements can lead to errors in diabetes management, including taking the wrong dose of insulin, sulfonylureas, or other medications that can rapidly lower blood glucose.
Smartwatches measuring glucose level: Harmful but easy to buy fake innovations
How to introduce innovation and AI in healthcare organizations if there is no business model for prevention and quality – Our interview with Professor Ran Balicer, the Chief Innovation Officer at Clalit Health Services and founding Director of Clalit Research Institute.
I see no legitimate rationale for delaying the digital transformation in healthcare
Pioneering Cardiac Arrest Detection for Enhanced Survival.
CardioWatch Revolutionizes Cardiac Arrest Detection
Dr. Oscar Díaz-Cambronero, Head of Perioperative Medicine Department at La Fe Hospital, spearheads innovative telemonitoring initiatives revolutionizing patient care
Smartwatches Saving Lives Inside and Outside the Hospital
EIT 2024
EIT Awards 2024. Two European startups are revolutionizing the treatment of cardiovascular diseases
Bertrand Piccard, Swiss explorer and founder of the Solar Impulse Foundation
EIT Summit 2024. What are the trigger points that drive or inhibit innovation?
MMC pioneers wireless monitoring for premature infants with the innovative Bambi Belt, revolutionizing care with improved comfort and mobility.
Wireless Monitoring of Vital Signs in Premature Infants at Máxima MC
Follow us